<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02713698</url>
  </required_header>
  <id_info>
    <org_study_id>2015.221(183-DEFI/165-CES)</org_study_id>
    <nct_id>NCT02713698</nct_id>
  </id_info>
  <brief_title>Propofol Pharmacokinetics and Pharmacodynamics Modelling</brief_title>
  <official_title>Modelling Propofol Pharmacokinetics and Pharmacodynamics During an Intravenous Anaesthesia Guided by the Bispectral Index (BIS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centro Hospitalar do Porto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centro Hospitalar do Porto</source>
  <brief_summary>
    <textblock>
      The main purpose of this research is to develop a population pharmacokinetic and
      pharmacodynamic model of Propofol when used for induction and maintenance of anaesthesia,
      using BIS as a pharmacodynamic endpoint.

      A covariate analysis will be performed in order to account for variability in pharmacokinetic
      and pharmacodynamic parameters. The influence of age and obesity on propofol pharmacokinetic
      parameters will be particularly addressed.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 1, 2016</start_date>
  <completion_date type="Actual">April 28, 2017</completion_date>
  <primary_completion_date type="Actual">April 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma Propofol Concentration (mcg/mL)</measure>
    <time_frame>up to 2 hours</time_frame>
    <description>Arterial blood samples were obtained after LOC and every 20-30 minutes during propofol infusion. After stopping propofol infusion, arterial blood samples were obtained immediately after recovery of consciousness.
At the end of the surgery arterial blood samples were centrifuged at 2862xg for 5 minutes and they were preserved at -80ºC until analysis.
The quantification of propofol in serum was performed using gas chromatography/ion trap-mass spectrometry (GC/IT-MS)</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">60</enrollment>
  <condition>Intravenous Anesthetic Agent Overdose</condition>
  <arm_group>
    <arm_group_label>Group 1 (≥18 years, BMI&lt;35kg/m2)</arm_group_label>
    <description>Patients with 18 or more years presenting for inpatient nose and ear surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 (≥18 years, ≥35kg/m2)</arm_group_label>
    <description>Patients with 18 or more years presenting for inpatient bariatric surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3 (≥65 years)</arm_group_label>
    <description>Patients with 65 or more years presenting for orthopaedic surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol</intervention_name>
    <description>The whole anaesthetic procedure is standard except for additional body composition assessment with Body Composition Monitor - BCM (Fresenius Medical Care, Germany) and arterial blood samples collection.
In all included patients, propofol will be started at 2000mg/h until LOC, defined by &quot;loss of eye-lash reflex&quot; and &quot;loss of response to name calling&quot;. During surgery propofol infusion will be guided by targeted BIS values between 40 and 60.
Arterial blood samples will be obtained immediately after LOC and after every 20-30 minutes during propofol infusion. After stopping propofol infusion, arterial blood samples will be acquired every 10 minutes until recovery of consciousness. The maximum blood sample per patient will be 20 mL.</description>
    <arm_group_label>Group 1 (≥18 years, BMI&lt;35kg/m2)</arm_group_label>
    <arm_group_label>Group 2 (≥18 years, ≥35kg/m2)</arm_group_label>
    <arm_group_label>Group 3 (≥65 years)</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Arterial blood samples will be collected in serum tubes and centrifuged at 2000 rpm for 15
      minutes in order to obtain serum. Serum will be preserved at -80ºC until analysis.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Inpatient care at Centro Hospitalar do Porto
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients admitted for nose or ear surgery, bariatric surgery or urgent
             orthopaedic surgery.

        Exclusion Criteria:

          -  Severe hepatic or renal insufficiency;

          -  Significant haemodynamic instability previous to the surgery;

          -  Allergy to eggs or propofol at the time of enrolment;

          -  Predictive criteria for difficult airway management.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Centro Hospitalar do Porto</name>
      <address>
        <city>Porto</city>
        <zip>4099-001</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Portugal</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>February 23, 2016</study_first_submitted>
  <study_first_submitted_qc>March 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 21, 2016</study_first_posted>
  <results_first_submitted>January 24, 2018</results_first_submitted>
  <results_first_submitted_qc>September 22, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">September 26, 2018</results_first_posted>
  <last_update_submitted>September 22, 2018</last_update_submitted>
  <last_update_submitted_qc>September 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centro Hospitalar do Porto</investigator_affiliation>
    <investigator_full_name>Ana M Araujo</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Anaesthetics</keyword>
  <keyword>Intravenous</keyword>
  <keyword>Propofol</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Pharmacodynamics</keyword>
  <keyword>Propofol pharmacokinetic-pharmacodynamic model</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Drug Overdose</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propofol</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 8, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/98/NCT02713698/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Group 1 (≥18 Years, BMI&lt;35kg/m2)</title>
          <description>Patients with 18 or more years presenting for inpatient nose and ear surgery.</description>
        </group>
        <group group_id="P2">
          <title>Group 2 (≥18 Years, BMI≥35kg/m2)</title>
          <description>Patients with 18 or more years presenting for inpatient bariatric surgery.</description>
        </group>
        <group group_id="P3">
          <title>Group 3 (≥65 Years)</title>
          <description>Patients with 65 or more years presenting for urgent orthopaedic surgery.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group 1 (≥18 Years, BMI&lt;35kg/m2)</title>
          <description>Patients with 18 or more years presenting for inpatient nose and ear surgery.</description>
        </group>
        <group group_id="B2">
          <title>Group 2 (≥18 Years, BMI≥35kg/m2)</title>
          <description>Patients with 18 or more years presenting for inpatient bariatric surgery.</description>
        </group>
        <group group_id="B3">
          <title>Group 3 (≥65 Years)</title>
          <description>Patients with 65 or more years presenting for urgent orthopaedic surgery.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="20"/>
            <count group_id="B4" value="60"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.7" spread="12.5"/>
                    <measurement group_id="B2" value="47.9" spread="9.4"/>
                    <measurement group_id="B3" value="77.7" spread="8.6"/>
                    <measurement group_id="B4" value="56.4" spread="18.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="44"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="60"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Portugal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Plasma Propofol Concentration (mcg/mL)</title>
        <description>Arterial blood samples were obtained after LOC and every 20-30 minutes during propofol infusion. After stopping propofol infusion, arterial blood samples were obtained immediately after recovery of consciousness.
At the end of the surgery arterial blood samples were centrifuged at 2862xg for 5 minutes and they were preserved at -80ºC until analysis.
The quantification of propofol in serum was performed using gas chromatography/ion trap-mass spectrometry (GC/IT-MS)</description>
        <time_frame>up to 2 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1 (≥18 Years, BMI&lt;35kg/m2)</title>
            <description>Patients with 18 or more years presenting for inpatient nose and ear surgery.</description>
          </group>
          <group group_id="O2">
            <title>Group 2 (≥18 Years, BMI≥35kg/m2)</title>
            <description>Patients with 18 or more years presenting for inpatient bariatric surgery.</description>
          </group>
          <group group_id="O3">
            <title>Group 3 (≥65 Years)</title>
            <description>Patients with 65 or more years presenting for urgent orthopaedic surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Propofol Concentration (mcg/mL)</title>
          <description>Arterial blood samples were obtained after LOC and every 20-30 minutes during propofol infusion. After stopping propofol infusion, arterial blood samples were obtained immediately after recovery of consciousness.
At the end of the surgery arterial blood samples were centrifuged at 2862xg for 5 minutes and they were preserved at -80ºC until analysis.
The quantification of propofol in serum was performed using gas chromatography/ion trap-mass spectrometry (GC/IT-MS)</description>
          <units>mcg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.36" spread="1.38"/>
                    <measurement group_id="O2" value="3.12" spread="1.5"/>
                    <measurement group_id="O3" value="2.91" spread="2.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Perioperative period</time_frame>
      <desc>The proposed study is a cross sectional analytical study.The whole anaesthetic procedure was standard except for additional body composition assessment with Body Composition Monitor - BCM (Fresenius Medical Care, Germany) and arterial blood samples collection.</desc>
      <group_list>
        <group group_id="E1">
          <title>Group 1 (≥18 Years, BMI&lt;35kg/m2)</title>
          <description>Patients with 18 or more years presenting for inpatient nose and ear surgery.</description>
        </group>
        <group group_id="E2">
          <title>Group 2 (≥18 Years, BMI≥35kg/m2)</title>
          <description>Patients with 18 or more years presenting for inpatient bariatric surgery.</description>
        </group>
        <group group_id="E3">
          <title>Group 3 (≥65 Years)</title>
          <description>Patients with 65 or more years presenting for urgent orthopaedic surgery.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Mean arterial pressure (MAP) variation &gt;40% after induction of general anesthesia</sub_title>
                <description>Patients in whom a variation higher than 40% was registered after induction of general anesthesia were treated with ephedrine and fluid boluses to return MAP to baseline levels.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ana Maria Araujo</name_or_title>
      <organization>Centro Hospitalar do Porto</organization>
      <phone>22 2077549 ext 1280</phone>
      <email>amfariaaraujo@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

